| Price | $0.63 |
| Year Range | $0.63 – $382.5 |
| Market Cap | $10M |
| PE Ratio | 0 |
| Industry | Biotechnology |
What Is Conduit Pharmaceuticals’s AI Stock Analysis?
Conduit Pharmaceuticals’s AI stock analysis on AltIndex combines the company’s fundamentals, price technicals and 25+ alternative data signals — like hiring, web traffic, app downloads and online sentiment — into a single AI Score from 0 to 100 and a plain-English Buy, Hold or Sell read. Unlike a traditional analyst rating that updates a few times a year, the AI Score refreshes as new data arrives, so it tracks Conduit Pharmaceuticals’s momentum in near-real time.
Conduit Pharmaceuticals (CDT) has an AltIndex AI Score of 48/100, currently a Hold signal. The AI Score distills Conduit Pharmaceuticals's fundamentals, price technicals and 25+ alternative data signals into a single 0–100 rating, so a rising score reflects strengthening data across the board and a falling score the opposite.
Conduit Pharmaceuticals’s Full AI Analysis
Keep reading AltIndex’s full AI analysis of Conduit Pharmaceuticals — the fundamental, technical and alternative-data breakdown and the recommendation.
Sign up to read the full analysisWhat’s Driving CDT’s AI Score?
Fundamentals
Revenue for the last quarter was $750M. This is an increase of 7.72% compared to the quarter before it, which is a positive sign of growth. Compared to the same quarter last year, there is an increase of 11.63%, suggesting positive year-over-year growth. Net income for the last quarter was $69M. This is an increase of 34.31% compared to the quarter before it, which is a positive sign of growth. Compared to the same quarter last year, there is an increase of -1,236.96%, suggesting positive year-over-year growth. Ebitda for the last quarter was $160M. This is an increase of 46.90% compared to the quarter before it, which is a positive sign of growth. Compared to the same quarter last year, there is an increase of -3,204.34%, suggesting positive year-over-year growth. A negative or zero P/E ratio indicates the company is not currently profitable. In the last couple of months, there's been a couple of company insiders selling their stock, a potentially bearish signal.
See Conduit Pharmaceuticals’s earnings and insider transactions.
Technicals
Today's stock price is $0.63. This represents a decrease of 79.94% compared to a month ago, which may be concerning in the short-term. However, compared to a year ago, there is a decrease of 99.97%, which could be a cause for long-term concern. The trend is bearish. The current SMA10 is $1.43, which is lower than the previous SMA10 of $1.57. This suggests a potential downward trend in price movement. The RSI is 30.7, indicating a neutral condition.
See the full technical analysis and price prediction.
Alternative data
Conduit Pharmaceuticals has an estimate of 0 visitors to their webpage, with no meaningful increase or decrese in the last couple of months.
Explore Conduit Pharmaceuticals’s job postings, web traffic and app downloads.
Sentiment & social
The sentiment for the stock on various stock forums is high, a positive sign.
Track Conduit Pharmaceuticals’s market sentiment.
Frequently Asked Questions: Conduit Pharmaceuticals AI Stock Analysis
Conduit Pharmaceuticals's AltIndex AI Score is 48/100, currently a Hold signal. The AI Score blends fundamentals, technicals and 25+ alternative data signals into a single rating from 0 to 100.
AltIndex's AI Score model rates Conduit Pharmaceuticals a Hold (48/100). This is a data-driven signal, not investment advice — review the breakdown above and combine it with your own research.
The AI Score is generated from fundamental data (earnings, valuation), technical indicators (price trend and momentum), and alternative data signals such as hiring, web traffic, app downloads and sentiment. AltIndex weighs these into a single 0-100 score; the exact weighting is proprietary.
AltIndex generates a complete written AI analysis of Conduit Pharmaceuticals — company overview, fundamentals, technicals and alternative data, with a recommendation. See the CDT AI Score or sign up to read the full thesis.
